The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)
This study has suspended participant recruitment.
(Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the ALTITUDE clinical trial found a higher incidence of adverse events.)
Sponsor:
University of Michigan
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Kenneth A. Jamerson, University of Michigan Health System
ClinicalTrials.gov Identifier:
NCT01432106
First received: September 8, 2011
Last updated: August 23, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has suspended participant recruitment. |
|---|---|
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |